Depression remains a major global health burden, and conventional antidepressants, although effective, are limited by side effects and withdrawal symptoms.
Aim:
To map umbrella-level evidence on single-agent nutraceutical and herbal interventions for clinically diagnosed depression in adults.
Methods:
This scoping review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews and Joanna Briggs Institute guidance. PubMed, PsycINFO, Scopus, and Cochrane Library were searched (2015–2025) for umbrella reviews assessing oral nutraceuticals or herbal medicines for depression.
Results:
Nine umbrella reviews met inclusion criteria, covering omega-3 fatty acids, vitamin D, probiotics, saffron, St John’s wort, zinc, and folate. Umbrella reviews generally reported potential antidepressant benefits and acceptable safety profiles for several interventions, although trial overlap and heterogeneity limited certainty.
Conclusions:
Evidence indicates promising but inconsistent efficacy across several nutraceutical and herbal agents. Standardized reporting, consideration of baseline nutrient status, and economic evaluation are needed to clarify their role in depression care.
SayyahM, EslamiK, AlaiShehniS, et al.Cognitive function before and during treatment with selective serotonin reuptake inhibitors in patients with depression or obsessive-compulsive disorder. Psychiatry J2016;2016:5480391; doi: 10.1155/2016/5480391
3.
BalaA, NguyenHMT, HellstromWJG. Post-SSRI sexual dysfunction: A literature review. Sex Med Rev2018;6(1):29–34; doi: 10.1016/j.sxmr.2017.07.002
4.
MontejoAL, MontejoL, BaldwinDS. The impact of severe mental disorders and psychotropic medications on sexual health and its implications for clinical management. World Psychiatry2018;17(1):3–11; doi: 10.1002/wps.20509
5.
ShrivastavaA, JohnstonME. Weight-gain in psychiatric treatment: Risks, implications, and strategies for prevention and management. Mens Sana Monogr2010;8(1):53–68; doi: 10.4103/0973-1229.58819
6.
GilibertoS, ShishodiaR, NastruzM, et al.A comprehensive review of Novel FDA-approved psychiatric medications (2018–2022). Cureus2024;16(3):e56561; doi: 10.7759/cureus.56561
7.
DaviesJ, ReadJ. A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: Are guidelines evidence-based? Addict Behav2019;97:111–121; doi: 10.1016/j.addbeh.2018.08.027
8.
PrakashSE, ManjunathaVC, NagellaP, et al.Nutraceuticals to prevent and manage cardiovascular diseases. In: Nutraceuticals: Sources, Processing Methods, Properties, and Applications. Elsevier; 2023;269–291; doi: 10.1016/B978-0-443-19193-0.00011-3
9.
GholipourD, ShahrakiM, ShakibaM, et al.Supplementation of Omega‐3 increases serum levels of brain‐derived neurotrophic factor and decreases depression status in patients with bipolar disorder: A randomized, double‐blind, placebo‐controlled clinical trial. J Hum Nutr Diet2025;38(3):e70076; doi: 10.1111/jhn.70076
10.
OteroMC, CericF, Miranda-RojasS, et al.Documentary analysis of Hypericum perforatum (St. John’s Wort) and its effect on depressive disorders. Pharmaceuticals (Basel)2024;17(12):1625; doi: 10.3390/ph17121625
11.
HamedaniSG-, PourmasoumiM, ZarifiSH, et al.Therapeutic effects of saffron and its components on neurodegenerative diseases. Heliyon2024;10(2):e24334; doi: 10.1016/j.heliyon.2024.e24334
12.
MoldoveanuC-A, Tomoaia-CotiselM, Sevastre-BerghianA, et al.A review on current aspects of curcumin-based effects in relation to neurodegenerative, neuroinflammatory and cerebrovascular diseases. Molecules2024;30(1):43; doi: 10.3390/molecules30010043
13.
ParlettaN, ZarnowieckiD, ChoJ, et al.A Mediterranean-style dietary intervention supplemented with fish oil improves diet quality and mental health in people with depression: A randomized controlled trial (HELFIMED). Nutr Neurosci2019;22(7):474–487; doi: 10.1080/1028415X.2017.1411320
14.
Bizzozero-PeroniB, Martínez-VizcaínoV, Fernández-RodríguezR, et al.The impact of the Mediterranean diet on alleviating depressive symptoms in adults: A systematic review and meta-analysis of randomized controlled trials. Nutr Rev2025;83(1):29–39; doi: 10.1093/nutrit/nuad176
15.
AllcockL, MantziorisE, VillaniA. Adherence to a mediterranean diet is inversely associated with anxiety and stress but not depression: A cross-sectional analysis of community-dwelling older Australians. Nutrients2024;16(3):366; doi: 10.3390/nu16030366
16.
AlliSR, GorbovskayaI, LiuJCW, et al.The gut microbiome in depression and potential benefit of prebiotics, probiotics and synbiotics: A systematic review of clinical trials and observational studies. Int J Mol Sci2022;23(9):4494; doi: 10.3390/ijms23094494
17.
HausenblasHA, HeekinK, MutchieHL, et al.A systematic review of randomized controlled trials examining the effectiveness of saffron (Crocus sativus L.) on psychological and behavioral outcomes. J Integr Med2015;13(4):231–240; doi: 10.1016/S2095-4964(15)60176-5
18.
MatiasJN, AcheteG, CampanariGSDS, et al.A systematic review of the antidepressant effects of curcumin: Beyond monoamines theory. Aust N Z J Psychiatry2021;55(5):451–462; doi: 10.1177/0004867421998795
19.
ZhaoX, ZhangH, WuY, et al.The efficacy and safety of St. John’s Wort extract in depression therapy compared to SSRIs in adults: A meta-analysis of randomized clinical trials. Adv Clin Exp Med2023;32(2):151–161; doi: 10.17219/acem/152942
20.
SarrisJ, RavindranA, YathamLN, et al.Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: The World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) Taskforce. World J Biol Psychiatry2022;23(6):424–455; doi: 10.1080/15622975.2021.2013041
21.
TriccoAC, LillieE, ZarinW, et al.PRISMA extension for scoping reviews (PRISMA-ScR): Checklist and explanation. Ann Intern Med2018;169(7):467–473; doi: 10.7326/M18-0850
22.
TzigkounakisG. Current evidence from umbrella reviews on nutraceuticals and herbal medicine as first-line therapies for depression in adults: A scoping review. OSF Registrations2025.
23.
PetersMDJ, GodfreyCM, KhalilH, et al.Guidance for conducting systematic scoping reviews. Int J Evid Based Healthc2015;13(3):141–146; doi: 10.1097/XEB.0000000000000050
24.
PollockM, FernandesRM, BeckerLA, et al.What guidance is available for researchers conducting overviews of reviews of healthcare interventions? A scoping review and qualitative metasummary. Syst Rev2016;5(1):190; doi: 10.1186/s13643-016-0367-5
25.
GaoX, SuX, HanX, et al.Unsaturated fatty acids in mental disorders: An umbrella review of meta‐analyses. Adv Nutr2022;13(6):2217–2236; doi: 10.1093/advances/nmac084
26.
LuY, QiaoD, MiG. Clinical impacts of n-3 fatty acids supplementation on depression symptoms: An umbrella review of meta-analyses. Br J Nutr2024;131(5):841–850; doi: 10.1017/S000711452300226X
27.
MusazadehV, KeramatiM, GhalichiF, et al.Vitamin D protects against depression: Evidence from an umbrella meta-analysis on interventional and observational meta-analyses. Pharmacol Res2023;187:106605; doi: 10.1016/j.phrs.2022.106605
28.
MusazadehV, ZarezadehM, FaghfouriAH, et al.Probiotics as an effective therapeutic approach in alleviating depression symptoms: An umbrella meta-analysis. Crit Rev Food Sci Nutr2023;63(26):8292–8300; doi: 10.1080/10408398.2022.2051164
29.
MusazadehV, ZarezadehM, FaghfouriAH, et al.Saffron, as an adjunct therapy, contributes to relieve depression symptoms: An umbrella meta-analysis. Pharmacol Res2022;175:105963; doi: 10.1016/j.phrs.2021.105963
30.
FirthJ, TeasdaleSB, AllottK, et al.The efficacy and safety of nutrient supplements in the treatment of mental disorders: A meta‐review of meta‐analyses of randomized controlled trials. World Psychiatry2019;18(3):308–324; doi: 10.1002/wps.20672
31.
SarrisJ, MarxW, AshtonMM, et al.Plant-based medicines (phytoceuticals) in the treatment of psychiatric disorders: A meta-review of meta-analyses of randomized controlled trials: Les médicaments à base de plantes (phytoceutiques) dans le traitement des troubles psychiatriques: Une méta-revue des méta-analyses d’essais randomisés contrôlés. Can J Psychiatry2021;66(10):849–862; doi: 10.1177/0706743720979917
32.
XuY, ZengL, ZouK, et al.Role of dietary factors in the prevention and treatment for depression: An umbrella review of meta-analyses of prospective studies. Transl Psychiatry2021;11(1):478; doi: 10.1038/s41398-021-01590-6
33.
LiuY, YangR, ZhangN, et al.The efficacy and safety of complementary and alternative medicine for depression: An umbrella review. Braz J Psychiatry2024;46:e20243705; doi: 10.47626/1516-4446-2024-3705
34.
SarrisJ. Herbal medicines in the treatment of psychiatric disorders: 10-year updated review. Phytother Res2018;32(7):1147–1162; doi: 10.1002/ptr.6055
35.
ZandifarA, BadrfamR, MohammaditabarM, et al.The effect of prebiotics and probiotics on levels of depression, anxiety, and cognitive function: A Meta‐Analysis of Randomized Clinical Trials. Brain Behav2025;15(3):e70401; doi: 10.1002/brb3.70401
36.
SheaBJ, ReevesBC, WellsG, et al.AMSTAR 2: A critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ2017;358:j4008; doi: 10.1136/bmj.j4008
37.
WilliamsJW, MulrowCD, ChiquetteE, et al.A Systematic review of newer pharmacotherapies for depression in adults: Evidence report summary: Clinical guideline, part 2. Ann Intern Med2000;132(9):743–756; doi: 10.7326/0003-4819-132-9-200005020-00011
38.
RahimiR, NikfarS, AbdollahiM. Efficacy and tolerability of Hypericum perforatum in major depressive disorder in comparison with selective serotonin reuptake inhibitors: A meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry2009;33(1):118–127; doi: 10.1016/j.pnpbp.2008.10.018
39.
ApaydinEA, MaherAR, ShanmanR, et al.A systematic review of St. John’s Wort for major depressive disorder. Syst Rev2016;5(1):148; doi: 10.1186/s13643-016-0325-2
40.
NgQX, VenkatanarayananN, HoCYX. Clinical use of Hypericum perforatum (St John’s Wort) in depression: A meta-analysis. J Affect Disord2017;210:211–221; doi: 10.1016/j.jad.2016.12.048
41.
ForsdikeK, PirottaM. St John’s Wort for depression: Scoping review about perceptions and use by general practitioners in clinical practice. J Pharm Pharmacol2019;71(1):117–128; doi: 10.1111/jphp.12775
42.
LindeK, BernerM, EggerM, et al.St John’s Wort for depression. Br J Psychiatry2005;186(2):99–107; doi: 10.1192/bjp.186.2.99
43.
GasterB, HolroydJ. St John’s Wort for depression. Arch Intern Med2000;160(2):152; doi: 10.1001/archinte.160.2.152
44.
KasperS, GastparM, MöllerH-J, et al.Better tolerability of St. John’s Wort extract WS 5570 compared to treatment with SSRIs: A reanalysis of data from controlled clinical trials in acute major depression. Int Clin Psychopharmacol2010;25(4):204–213; doi: 10.1097/YIC.0b013e328335dc1a
45.
SwardfagerW, HerrmannN, MazereeuwG, et al.Zinc in depression: A meta-analysis. Biol Psychiatry2013;74(12):872–878; doi: 10.1016/j.biopsych.2013.05.008
46.
YosaeeS, ClarkCCT, KeshtkaranZ, et al.Zinc in depression: From development to treatment: A comparative/dose response meta-analysis of observational studies and randomized controlled trials. Gen Hosp Psychiatry2022;74:110–117; doi: 10.1016/j.genhosppsych.2020.08.001
47.
MorrisMS, FavaM, JacquesPF, et al.Depression and folate status in the US population. Psychother Psychosom2003;72(2):80–87; doi: 10.1159/000068692
48.
PapakostasGI, PetersenT, MischoulonD, et al.Serum folate, vitamin B12, and homocysteine in major depressive disorder, part 2. J Clin Psychiatry2004;65(8):1096–1098; doi: 10.4088/JCP.v65n0811
49.
BotturiA, CiappolinoV, DelvecchioG, et al.The role and the effect of magnesium in mental disorders: A systematic review. Nutrients2020;12(6):1661; doi: 10.3390/nu12061661
50.
de OliveiraC, HiraniV, BiddulphJP. Associations between vitamin D levels and depressive symptoms in later life: Evidence from the English Longitudinal Study of Ageing (ELSA). J Gerontol A Biol Sci Med Sci2018;73(10):1377–1382; doi: 10.1093/gerona/glx130
51.
AnglinRES, SamaanZ, WalterSD, et al.Vitamin D deficiency and depression in adults: Systematic review and meta-analysis. Br J Psychiatry2013;202(2):100–107; doi: 10.1192/bjp.bp.111.106666
52.
SherchandO, SapkotaN, ChaudhariRK, et al.Association between vitamin D deficiency and depression in Nepalese population. Psychiatry Res2018;267:266–271; doi: 10.1016/j.psychres.2018.06.018
53.
CarneyRM, SteinmeyerBC, FreedlandKE, et al.Baseline blood levels of omega-3 and depression remission. J Clin Psychiatry2016;77(02):e138–e143; doi: 10.4088/JCP.14m09660
54.
SchmierJK, RachmanNJ, HalpernMT. The cost-effectiveness of omega-3 supplements for prevention of secondary coronary events. Manag Care2006;15(4):43–50.
55.
KimMS, KimJM, LeeSG, et al.Assessing health and economic benefits of omega-3 fatty acid supplementation on cardiovascular disease in the Republic of Korea. Healthcare (Basel)2023;11(16):2365; doi: 10.3390/healthcare11162365
56.
PradelliL, EandiM, PoveroM, et al.Cost-effectiveness of omega-3 fatty acid supplements in parenteral nutrition therapy in hospitals: A discrete event simulation model. Clin Nutr2014;33(5):785–792; doi: 10.1016/j.clnu.2013.11.016
57.
WattersCA, EdmondsCM, et al.A cost analysis of EPA and DHA in fish, supplements, and foods. J Nutr Food Sci2012; 2(8); doi: 10.4172/2155-9600.1000159
KumarA, DeviM, KumarR, et al.Introduction of high-value Crocus sativus (saffron) cultivation in non-traditional regions of India through ecological modelling. Sci Rep2022;12(1):11925; doi: 10.1038/s41598-022-15907-y
60.
AkhondzadehS, Tahmacebi‐PourN, NoorbalaA, et al.Crocus sativus L. in the treatment of mild to moderate depression: A double‐blind, randomized and placebo‐controlled trial. Phytother Res2005;19(2):148–151; doi: 10.1002/ptr.1647
61.
MoshiriE, BastiAA, NoorbalaA-A, et al.Crocus sativus L. (petal) in the treatment of mild-to-moderate depression: A double-blind, randomized and placebo-controlled trial. Phytomedicine2006;13(9–10):607–611; doi: 10.1016/j.phymed.2006.08.006
62.
MohajeriD, MousaviG, MesgariM, et al.Subacute toxicity of crocus sativus L. (Saffron) stigma ethanolic extract in rats. Am J Pharmacol Toxicol2007;2(4):189–193; doi: 10.3844/ajptsp.2007.189.193
63.
SolomonD, AdamsJ, GravesN. Economic evaluation of St. John’s Wort (Hypericum perforatum) for the treatment of mild to moderate depression. J Affect Disord2013;148(2–3):228–234; doi: 10.1016/j.jad.2012.11.064
64.
AhmadSM, MasroorD, AzharI, et al.Retrospective cost-utility and budget impact assessments of Hypericum perforatum in contrast with Fluoxetine treatment for depression in Karachi, Pakistan. Braz J Pharm Sci2019;55; doi: 10.1590/s2175-97902019000217210
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
